PAX3 and neoplasm: As such, using in vitro and in vivo CAR-T based approaches, FGFR4 has been targeted causing specific cytotoxicity in vitro and decreased tumor burden in vivo in an intramuscular PAX3::FOXO1 xenograft model (137, 138).